The 14 analysts offering 12-month price forecasts for Arrowhead Pharmaceuticals Inc have a median target of 59.50, with a high estimate of 90.00 and a low estimate of 27.00. The median estimate represents a +118.35% increase from the last price of 27.25.
The current consensus among 14 polled investment analysts is to Buy stock in Arrowhead Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.69
Reporting Date Nov 27
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.